Skip to main content
Free shipping on all orders
888-559-3802
Shop
Learn
For Practitioners
At-Home Lab Testing
VitabaseGPT
Specials
Go back
VitabaseIngredients

Dimorphandra gardneriana

Table of contents

Other Names

anta beanDimorphandra biretusaDimorphandra biretusa Tul.fava d'antafaveirafaveiro

Synopsis

Dimorphandra gardneriana

1. Identity: Botanical Classification, Common Names, and Natural Source

Dimorphandra gardneriana Tulasne (abbreviated D. gardneriana Tul.) is the accepted scientific name for a flowering tree in the family Fabaceae (legumes). It belongs to the order Fabales, family Fabaceae, genus Dimorphandra. The species was formally described by the botanist Louis René Tulasne and published in 1844. It has one accepted synonym, Dimorphandra biretusa Tul., and is distributed across Bolivia, Brazil North, Brazil Northeast, Brazil Southeast, and Brazil West-Central.

The tree is popularly known as fava d'anta or faveira. Dimorphandra gardneriana, known as "fava d'anta" and "faveiro," is naturally found in South America, in Brazil and in Bolivia. It is a tree in the legume family native to the Brazilian states and regions of Piauí, Ceará, the Cerrado, Minas Gerais, Maranhão, the Caatinga, Bahia, Goiás, Pará, Tocantins, Pernambuco, and Mato Grosso.

Dimorphandra gardneriana is a small tree with a wide, low, dense crown, capable of growing 4–18 metres tall. Its seeds are medium-sized, with an average length of 11.95 mm, width of 5.33 mm, and thickness of 4.3 mm, unitegmic with a hard tegument, and impermeable to water. The tree is characteristic of the cerrado (Brazilian savanna) and caatinga (semi-arid scrubland) biomes. Dimorphandra gardneriana Tul. and Dimorphandra mollis Benth., popularly known as faveira and fava d'anta, are common trees in the cerrado (savannah-like) ecosystems of Brazil; D. gardneriana grows in Bahia and the Serra do Araripe (Ceará).

Both D. gardneriana and the closely related Dimorphandra mollis Benth. are commonly attributed the common name "fava d'anta." Dimorphandra mollis and Dimorphandra gardneriana are the scientific names commonly attributed to specimens known as "fava-d'anta," which face extinction risks due to overexploitation and habitat degradation, making the conservation of these species essential to preserve valuable genetic resources with potential applications in pharmaceutics and cosmetics.

1.1 Commercial Forms and Preparations

The primary commercially relevant part of the plant is its fruit. Dimorphandra gardneriana, popularly known as fava d'anta, is a typical tree from the Brazilian cerrado of large extractive use, due to its fruits being rich sources of the flavonoid rutin, which has pharmacological properties of commercial interest, especially vasodilator and antioxidant. In the pharmaceutical industry, the fruits of the fava d'anta are used to extract quercetin and rutin, which are the basis for the production of medicines that work to treat varicose veins, hemorrhoids, circulatory system disorders and a variety of other conditions.

The fruits are exploited by extractivist communities to obtain rutin and quercetin, which are internationally traded bioflavonoids — two of the ten most exported phytochemicals in Brazil. In practice, the species enters commerce almost exclusively as a raw botanical material for industrial extraction of rutin and quercetin; the isolated flavonoids are then incorporated into pharmaceutical preparations (tablets, capsules, oral solutions, topical gels) rather than being sold as a crude whole-plant supplement. The seed endosperm also yields galactomannan polysaccharides that have been investigated as excipients and drug-delivery vehicles (see Section 4 below).

2. Traditional and Historical Use

2.1 Ethnobotanical Context

Research has evaluated the management systems and extractivist practices and related ethnoecological knowledge of Dimorphandra gardneriana (fava d'anta) in the semiarid region of Ceará, Northeast of Brazil. Fava d'anta produces fruits with high concentrations of bioflavonoids, substances with various pharmacological properties, being exploited by extractivist communities in the mosaic of protected areas in Chapada do Araripe, Ceará.

Ethnoecological knowledge has been concentrated in collectors who have been active for a longer time and/or plant the species, and three management systems have been identified that can impact fava d'anta populations in different ways, depending on the area and level of human interference. This indicates that harvest practices and management approaches are varied, with the most experienced harvesters holding the deepest local knowledge about sustainable collection.

In ethnobotanical surveys conducted in the cerrado and caatinga regions of northeastern Brazil, Dimorphandra gardneriana was the species most cited for pain in relevant medicinal plant surveys covering that category. In savanna areas of Pernambuco state, Dimorphandra gardneriana Tul. — recorded under the common name "faveira" — was used via decoction prepared from the fruit, taken orally, for injuries and phlegm.

2.2 Traditional Purposes

The traditional use of fava d'anta is primarily medicinal, with the fruits and pods exploited for their flavonoid content. Historically, communities in the Brazilian cerrado and caatinga have used preparations of the fruit — most commonly infusions or decoctions — to address circulatory complaints, inflammatory conditions, and pain. The shoots of D. gardneriana are used to produce rutin, a flavonoid with strong antioxidant properties and anti-inflammatory effects, and which strengthens capillaries and inhibits some cancerous and precancerous conditions.

The extractivist economy built around fava d'anta in Brazil's Chapada do Araripe region represents a contemporary continuation of longstanding local knowledge about the plant's value. The fava d'anta is regarded as a "plant for the future" in Brazil's Center-West and Northeast regions due to its adaptability, economic potential in the food industry, ecological role in soil conservation and biodiversity, and cultural significance, making it a sustainable resource.

3. Key Constituents and Active Compounds

3.1 Principal Phytochemicals

Dimorphandra gardneriana contains several bioactive compounds, including rutin, galactomannans, and quercetin; these compounds have demonstrated antioxidant, anti-inflammatory, and antimicrobial properties. The following are the major characterized constituents:

  • Rutin (also called rutoside, quercetin-3-O-rutinoside, or vitamin P): a flavonol glycoside consisting of quercetin as the aglycone bound to the disaccharide rutinose (rhamnose + glucose). This is the dominant commercially important compound in the fruits.
  • Quercetin: a flavonol polyphenol; the aglycone and metabolic product of rutin after hydrolysis in the gut.
  • Galactomannans: high-molecular-weight seed polysaccharides localized in the endosperm.

A coumarin, scoparone, was isolated from the related species Platymiscium floribundum stems, while the flavonoids rutin and quercetin were isolated from Dimorphandra gardneriana beans. These compounds were purified using silica gel column chromatography, eluted with organic solvents in mixtures of increasing polarity, and identified by spectral analysis.

Regarding the seed galactomannan specifically: A galactomannan was obtained from mature seeds of Dimorphandra gardneriana Tul., the plant from which rutin is extracted; extraction was based on manual separation of the endosperm, water dissolution, centrifugation and precipitation with ethanol, yielding 31%, similar to values reported for other Brazilian seeds and to that of guar gum. The monosaccharide composition was mannose 64.2%, galactose 34.7% and glucose 1.1%. The mannose/galactose ratio of the D. gardneriana galactomannan (1.84) is similar to values reported for galactomannans from other Brazilian seeds, and is the M/G value closest to that of guar gum (1.6–1.8).

3.2 Rutin: Chemical Identity and Structure

Rutin (Rut) is a natural flavonoid glycoside, appearing as a light yellow or light green crystalline powder. It is structurally classified as a flavonol glycoside, consisting of the flavonolic aglycone quercetin along with the disaccharide rutinose. It has demonstrated a number of pharmacological activities, including antioxidant, cytoprotective, vasoprotective, anticarcinogenic, neuroprotective and cardioprotective activities.

3.3 Quercetin: Chemical Identity

Quercetin is categorized as a flavonol, one of the six subclasses of flavonoid compounds. In vitro and in some animal models, quercetin, a polyphenol derived from plants, has a wide range of biological actions including anti-carcinogenic, anti-inflammatory and antiviral activities, as well as attenuating lipid peroxidation, platelet aggregation and capillary permeability. When rutin is ingested, gut microbiota and intestinal enzymes hydrolyze the sugar moiety, releasing quercetin as the primary circulating metabolite.

4. Established and Investigated Mechanisms of Action

4.1 Vascular and Capillary Effects

Flavonoids are natural compounds employed for the clinical management of vascular disorders, preventing capillary permeability, working as phlebotonics, and improving blood rheology, although their mechanism of action remains partially unknown. Rutin and quercetin both contribute to these effects. Rutin has a variety of pharmacological effects such as antioxidant, anti-inflammatory, antihypertensive, maintaining vascular elasticity and neuroprotection.

4.2 Antioxidant Mechanisms

Rutin has been shown to have an extensive array of pharmacological applications due to its numerous properties including antioxidant, anti-inflammatory, cardiovascular, neuroprotective, antidiabetic, and anticancer activities; various mechanisms have been found to be responsible for its antioxidant activities in both in vitro and in vivo models. For quercetin, these properties form the basis for potential benefits to overall health and disease resistance, including anti-carcinogenic, anti-inflammatory, antiviral, antioxidant, and psychostimulant activities, as well as the ability to inhibit lipid peroxidation, platelet aggregation and capillary permeability, and to stimulate mitochondrial biogenesis.

4.3 Anti-Inflammatory Pathways

Quercetin prevents TNF-α from directly activating extracellular signal-related kinase (ERK), c-Jun NH2-terminal kinase (JNK), c-Jun, and nuclear factor-κB (NF-κB), which are potent inducers of inflammatory gene expression and protein secretion; additionally, quercetin may indirectly prevent inflammation by increasing peroxisome proliferator-activated receptor γ (PPARγ) activity, thereby antagonizing NF-κB or activator protein-1 (AP-1) transcriptional activation of inflammatory genes — together, these block TNF-α-mediated induction of inflammatory cascades.

For rutin specifically, the anti-inflammatory activity of rutin may be due to its modulation of the expression of the ASC (apoptosis-associated speck-like protein) complex. Rutin could be a candidate therapeutic agent for the treatment of various severe vascular inflammatory diseases via inhibition of the HMGB1 (high mobility group box 1) signaling pathway.

4.4 Neuroprotective Mechanisms

Rutin has demonstrated neuroprotective effects in brain ischemia. Administration of rutin caused attenuation of "ischemic neural apoptosis" due to suppression of p53 expression and lipid peroxidation along with increment in "endogenous antioxidant defense enzymes." Reduction of "neuroinflammation" in a rat model of "sporadic dementia of Alzheimer type" and neuroprotective effects in "dexamethasone-treated mice" were observed upon rutin administration.

4.5 Leishmanicidal and Cholinesterase-Inhibiting Mechanisms

A screen assay using luciferase-expressing promastigote form and an in-situ ELISA assay were used to measure the viability of promastigote and amastigote forms after exposure to D. gardneriana compounds; an MTT colorimetric assay was performed to determine toxicity in murine monocytic RAW 264.7 cell line, and all compounds were tested in vitro for their anti-cholinesterase properties. All compounds inhibited acetylcholinesterase (AChE) with inhibition zones varying from 0.8 to 0.6, indicating a possible mechanism of action for leishmanicidal activity.

4.6 Galactomannan: Antiviral Entry Inhibition

The sulfated galactomannans derived from D. gardneriana seeds have been studied as virus entry inhibitors. These polysaccharides were sulfated with chlorosulfonic acid and then the sulfated galactomannans were evaluated for antiradical activity and for inhibitory potential against DENV-2 (dengue virus serotype 2) in Vero cells. The galactomannans extracted from the seeds showed antiviral activity against the DENV-2 virus and significant antioxidant properties, suggesting that these compounds have promising potential as herbal medicines.

5. Scientific Evidence by Area of Use

5.1 Chronic Venous Insufficiency (CVI)

D. gardneriana-derived rutin is the basis for the phlebotonic drug class known as rutosides (or oxerutins/hydroxyethylrutosides), which have been investigated in European clinical trials for chronic venous insufficiency. It must be noted that the majority of clinical evidence relates specifically to isolated rutin or its semisynthetic derivatives (oxerutins/Venoruton), not to crude D. gardneriana fruit preparations as such.

Oxerutins, also called hydroxyethylrutosides, are a group of semisynthetic chemicals derived from the naturally occurring bioflavonoid rutin; this supplement has been widely used in Europe since the mid-1960s as a treatment for conditions in which blood or lymph vessels leak fluid.

In one study of 22 people with varicose veins and venous insufficiency, a higher dose had a faster effect than the lower dose (2 g/day vs. 1 g/day), but everyone experienced benefits in just 8 days; in another study on over 200 people, Venoruton (a rutoside preparation) was more effective than the combination of hesperidin and diosmin. Venoruton successfully controlled leg swelling in 4 clinical trials on over 300 people flying for 7–11 hours; all in all, the evidence suggests that rutin may help with vein problems.

Natural rutin supplements are often marketed as general vascular and antioxidant support, while medicinal rutosides are used more specifically as venoactive drugs for chronic venous insufficiency and related microcirculatory disorders. Natural rutin has relatively low oral bioavailability because it is poorly soluble in water and needs to be broken down by gut enzymes and microbiota. The evidence for the semisynthetic rutoside class in CVI is considered reasonably strong for symptom management and edema reduction; evidence for natural rutin supplementation at lower doses is less definitive due to bioavailability limitations.

5.2 Hemorrhoidal Disease

Rutin improved bleeding, pain, and inflammation in 2 clinical trials on 150 women with hemorrhoids due to pregnancy; a mixture of rutin and other flavonoids (diosmin, hesperidin, and quercetin) reduced hemorrhoid symptoms without causing adverse effects in another trial on 154 people; although limited, the evidence suggests that rutin may help with hemorrhoids.

In the pharmaceutical industry, the fruits of the fava d'anta are used to extract quercetin and rutin, which are the basis for the production of medicines that work to treat varicose veins, hemorrhoids, circulatory system disorders and a variety of other conditions. Rutosides have been used to reduce pain and swelling in hemorrhoidal disease, with variable but sometimes positive results. Overall, evidence for hemorrhoidal applications is preliminary and largely limited to combination phlebotonic products rather than D. gardneriana preparations per se.

5.3 Antioxidant Activity

The antioxidant activity of rutin extracted from D. gardneriana was evaluated using DPPH free radical scavenging activity, reaction with thiobarbituric acid, Fe²⁺ chelation, degradation of deoxyribose, and iron reduction; quercetin was used as a positive control. These are in vitro assays; clinical evidence for meaningful systemic antioxidant effects in humans from orally administered rutin from this plant source specifically remains limited.

5.4 Neuroprotection (Preclinical Evidence Only)

Research comprehensively evaluates rutin's multifaceted neuroprotective mechanisms, encompassing antioxidant, anti-inflammatory, anti-apoptotic, antidepressant, anticonvulsant, and analgesic effects, as well as its role in enhancing neural signal transduction, improving learning and memory, and protecting the blood-brain barrier. However, the biological activities of quercetin have been evaluated both in vitro and in vivo, involving a number of cell lines and animal models, but metabolic mechanisms in the human body are not clear; further large-sample clinical studies are needed to determine the appropriate dosage and form for treatment of disease.

Rutin is considered a promising agent for the treatment of Alzheimer's disease because of its antioxidant, anti-inflammatory, and β-amyloid oligomer-reducing activities; nitric oxide modulation could possibly be involved in neuroprotective effects of rutin against head trauma-induced cognitive deficits, neuroinflammation, and apoptotic signaling cascade. All such evidence remains at the preclinical (animal and cell-culture) stage at this time.

5.5 Antidiabetic Effects (Preclinical Evidence Only)

Rutin exhibited significant antidiabetic activity, presumably by inhibiting inflammatory cytokines, and improved the antioxidant and plasma lipid profiles in a high-fat diet plus streptozotocin-induced type 2 diabetic model; rutin may thus be useful as a diabetic modulator along with standard antidiabetic drugs. This evidence is entirely preclinical; no controlled human trials are available for diabetes treatment using D. gardneriana products directly.

5.6 Leishmanicidal Activity (In Vitro)

Rutin and quercetin, isolated from D. gardneriana grains, were evaluated for their leishmanicidal and cholinesterase inhibitory activity; the Leishmania infantum chagasi strain was cultivated in promastigote form and subjected to a leishmanicidal test in microplates with different concentrations of the compounds (100–6.25 μg/mL), using pentamidine as a positive control; viability of promastigotes was analyzed by microscopy and optical density; to evaluate the amastigote form, infected RAW 264.7 macrophages were treated for 48 h with viability determined by ELISA, using amphotericin B as a positive control; the study found that rutin and quercetin showed leishmanicidal activity on both promastigote and amastigote forms in a similar way to pentamidine and amphotericin B.

In the leishmanicidal assays, the compounds showed dose-dependent efficacy against the extracellular promastigote forms, with an EC50 for quercetin and rutin of 26 and 30.3 μg/mL, respectively. The flavonoids presented comparable results to the positive control drug, amphotericin B, against the amastigote forms with EC50 for quercetin and rutin of 10.6 and 43.3 μg/mL, respectively. This evidence is entirely in vitro; no clinical trials have evaluated D. gardneriana products in human leishmaniasis.

5.7 Antiviral Activity of Galactomannans (In Vitro)

Sulfonated derivatives of D. gardneriana seed galactomannans were combined with mangiferin and tested for antiviral effects. The galactomannan–mangiferin complex (DgGmM) showed a 50% cytotoxic concentration (CC50) of >2000 μg/mL; the 50% inhibitory concentrations (IC50) for HSV-1 and PV-1 were respectively 287.5 μg/mL and 206.2 μg/mL, with selectivity indices >6.95 for the former and >9.69 for the latter; the time-of-addition protocol for HSV-1 showed maximum inhibition at 500 μg/mL when added concomitantly at the time of infection. This evidence is in vitro and preclinical.

5.8 Intestinal Mucosal Protection (Preclinical)

Rutin, a natural flavonoid extracted from Dimorphandra gardneriana, exhibits antioxidant, anti-inflammatory, cytoprotective, and gastroprotective properties; however, the effect of rutin on inflammatory processes in the intestine, especially on mucositis promoted by antineoplastic agents, had not yet been reported; a study investigated the role of rutin on 5-fluorouracil-induced experimental intestinal mucositis. Swiss mice were randomly divided into seven groups: Saline, 5-FU, RUT-50, RUT-100, RUT-200, Celecoxib (CLX), and CLX + RUT-200 groups. The results of such preclinical experiments have not been replicated in human clinical trials.

5.9 Skin/Dermatological Effects

In a clinical trial on 40 middle-aged people, a topical cream with rutin increased skin elasticity and decreased the length, area, and number of wrinkles; rutin increased collagen production and reduced oxidative damage in skin cells in the same study. This trial used a topical rutin preparation; it does not directly evaluate oral D. gardneriana supplementation.

5.10 Overall Evidence Strength Assessment

The studies analyzed showed various pharmacological activities of compounds extracted from D. mollis and D. gardneriana species, including antioxidant, anti-inflammatory, neuroprotective, antiviral and lipid metabolism modulating properties; the presence of the flavonoids rutin and quercetin reinforces the potential of these species for therapeutic applications. Nevertheless, the large majority of this evidence derives from in vitro cell assays and animal models; robust, large-scale randomized controlled clinical trials using standardized D. gardneriana preparations as such are lacking. Clinical evidence for symptom relief in venous insufficiency and hemorrhoids comes from trials on isolated rutin or semi-synthetic rutoside drugs, not crude plant extracts.

6. Body Systems and Health Areas of Association

  • Cardiovascular and venous system: Capillary fragility, chronic venous insufficiency, varicose veins, edema, hemorrhoids — most clinically investigated area for the rutin constituent.
  • Nervous system: Neuroprotection against ischemia, neuroinflammation, and Alzheimer's-type neurodegeneration — evidence preclinical only.
  • Immune and infectious disease: Leishmanicidal activity, antiviral (dengue, herpes) — evidence in vitro only.
  • Metabolic/endocrine: Antidiabetic and lipid-modulating activities — evidence preclinical only.
  • Gastrointestinal: Gastroprotective and cytoprotective effects, mucosal protection — evidence preclinical only.
  • Integumentary (skin): Collagen synthesis support, antioxidant skin effects — limited clinical evidence from topical applications.
  • Oncology: Anticarcinogenic and pro-apoptotic effects for certain cancer cell lines — evidence in vitro and in animal models only.

7. Dosage Forms and Dosages Reported in Studies

The following dosages are those reported in cited scientific literature and apply to rutin (the principal active constituent extracted from D. gardneriana), not to crude plant preparations for which standardized human dosage data is unavailable.

  • In a study of 22 people with varicose veins and venous insufficiency using the rutoside preparation Venoruton, the higher dose had a faster effect than the lower dose: 2 g/day vs. 1 g/day, but everyone experienced benefits in just 8 days.
  • In an 8-month study of patients with severe chronic venous insufficiency, each person received a daily dosage of 1 g or 2 g, or none at all; additionally, all wore specialized compression stockings; while all experienced improvement, the best results were seen with the highest dosage.
  • In a preclinical mouse study of rutin on intestinal mucositis, dosing groups included RUT-50, RUT-100, and RUT-200 (mg/kg), administered to Swiss mice.
  • In a rat pharmacokinetic study investigating the interaction between rutin and warfarin, a single dose of racemic warfarin (1.5 mg/kg) was administered orally either alone or on day 5 of an 8-day oral regimen of rutin at 1 g/kg daily.

No clinically validated dosage range for oral supplementation of crude D. gardneriana fruit extract has been established in the peer-reviewed literature identified in this review. Extraction of rutin from D. gardneriana fruits has been evaluated using different solvents — methanol, ethanol, ethanol/water, and water — with the presence of rutin analyzed by Thin Layer Chromatography and High Performance Liquid Chromatography. Laboratory quantification methods such as HPLC are used to standardize the flavonoid content of extracts for research and pharmaceutical purposes.

8. Safety Considerations and Drug Interactions

8.1 General Safety Profile of Rutin

As a member of bioflavonoids, rutin is natural and considered safe, which makes it more advantageous than other chemical compounds as a potential therapeutic agent. Due to its high pharmacological activity and fewer adverse drug reactions, rutin has attracted significant interest. Studies on carcinogenicity of rutin have demonstrated practically no carcinogenic potential.

8.2 Warfarin Interaction

In a rat pharmacokinetic study, rutin reduced the anticoagulant effect of racemic warfarin, evident as a 31% reduction in the area under the prothrombin complex activity–time curve (P < 0.05); rutin had no apparent effect on pre-treatment baseline blood coagulation; it enhanced the in vitro serum protein binding of S- and R-warfarin (reflected by 40% and 26% reductions in unbound fraction), and treatment with rutin significantly decreased the elimination half-life of S-warfarin by 37% as a result of a 69% increase in unbound clearance of the S-enantiomer. Concurrent rutin administration is thus likely to reduce the anticoagulant effect of racemic warfarin, reflecting a significant decrease in the elimination half-life of the more potent S-enantiomer.

8.3 Paclitaxel (Taxol) Interaction

Absorption of paclitaxel is increased when concurrently administered with rutin. When given simultaneously, rutin increases the amount of paclitaxel absorbed by the body, and rutin treatment may further increase the body's resistance to certain medications. This pharmacokinetic interaction has been observed in animal studies and has not yet been fully evaluated in clinical settings.

8.4 Cytochrome P450 Interactions

Rutin may affect the metabolism of certain drugs processed by the liver's cytochrome P450 enzyme system; this can alter the blood levels and effectiveness of medications such as statins, certain antidepressants, and some antiepileptic drugs. Rutin treatment causes increased body resistance to drugs due to induction of drug-metabolizing enzymes in the liver; such an action has about the same magnitude as that of phenobarbital and pregnenolone-16α-carbonitrile.

8.5 Anticoagulant/Antiplatelet Drug Class Interactions

One of the primary concerns is rutin's interaction with anticoagulant and antiplatelet drugs such as warfarin, aspirin, and clopidogrel; additionally, rutin may interact with certain anti-inflammatory drugs (both steroidal and non-steroidal), potentially enhancing their effects and increasing the risk of gastrointestinal side effects like ulcers and bleeding.

8.6 Pregnancy and Breastfeeding

It is not known if or how rutin could affect pregnancy or harm a fetus. It is not known if rutin passes into breast milk; however, when rutin is taken by mouth, it turns into quercetin, which does pass into breast milk.

8.7 Conservation and Sustainability Concerns

A notable non-toxicological safety consideration relates to the ecological status of the plant itself. Dimorphandra mollis and Dimorphandra gardneriana face extinction risks due to overexploitation and habitat degradation, making the conservation of these species essential to preserve valuable genetic resources with potential applications in pharmaceutics and cosmetics. Despite progress made in local development, it is crucial to establish policies and promote the long-term sustainability of the production system; to effectively preserve the fava d'anta in the Araripe Region, it is necessary to carry out new studies and establish a conservation plan.

9. Research Gaps and Future Directions

Data collected from Scopus and Web of Science covering publications from 1969 to 2023 revealed a growing interest in this area of research, with a substantial number of citations and a wide range of covered topics including phytochemistry, biology, and pharmacology; most documents are original research articles, reflecting a strong focus on generating new empirical data, with notable contributions from Brazilian institutions; the importance of integrating traditional knowledge with scientific research to enhance the understanding and application of Dimorphandra species in public health has been underscored.

The properties of the plant's constituents form the basis for potential benefits to overall health and disease resistance, including anti-carcinogenic, anti-inflammatory, antiviral, antioxidant, and psychostimulant activities, as well as the ability to inhibit lipid peroxidation, platelet aggregation and capillary permeability, and to stimulate mitochondrial biogenesis; there is a pressing need for well-designed clinical trials to evaluate this novel dietary supplement further. Research has shown the potential of Dimorphandra gardneriana galactomannan and its sulfated derivative as novel bio-based materials for controlled release applications in pharmaceutical delivery systems.

References

Health Conditions

Health conditions that Dimorphandra gardneriana may help support.

  • No conditions available.

Body Systems

Body systems that Dimorphandra gardneriana may help support.

  • No body systems available.
Join our newsletter

Stay informed. Stay healthy.

Get expert supplement tips, exclusive discounts, and product recommendations delivered to your inbox